I
N ACUTE INTERVENTIONAL STROKE trials, functional outcomes as measured by various scales are used as the primary end points. 1, 2 This approach is limited by the low statistical power of these functional scales because of their ordinal scoring level. Furthermore, it has been shown that the choice of outcome measure may be crucial for the demonstration of therapeutic effects. [1] [2] [3] Infarct volume measured during brain imaging may function as a secondary end point, but the optimal time point and the best imaging modality for infarct volume measurements remain undefined. 4 Clinical long-term follow-up and repeated brain scans increase the associated labor and expenses. Therefore, there is a need for a surrogate marker in interventional stroke trials that is easily accessible, inexpensive, reliable, valid, and powerful with respect to clinically relevant outcome measures.
It has been shown previously that the astroglial protein S100B is elevated in peripheral blood in the first days after acute ischemic stroke. [5] [6] [7] [8] [9] [10] [11] [12] These authors described significant correlations between the cumulative S100B release estimated by the area under the curve (AUC), the final infarct volume, and the short-term outcome. [7] [8] [9] [10] [11] [12] Nevertheless, these promising findings have not established S100B as an end point in ongoing clinical trials, because the AUC, peak value, and other complex measures of the S100B kinetic require extensive blood sampling, which is not feasible in large-scale trials. Furthermore, the diagnostic accuracy of various single S100B values in predicting relevant outcome measures has not been evaluated prospectively, to our knowledge. Therefore, the objective of the present investigation was to test the predictive value of easily accessible S100B values for long-term outcome and infarct volume in a sample of patients experiencing stroke, for potential use in interventional stroke trials.
METHODS

STUDY POPULATION
We prospectively included 39 consecutive patients admitted to our stroke unit within 6 hours of symptom onset with suggested acute ischemia in the middle cerebral artery (MCA) territory, which was verified by means of a perfusion or diffusion deficit as seen on magnetic resonance imaging performed directly after hospital admission. 13 In case of magnetic resonance imaging contraindications (n=5), patients were included based on computed tomographic findings. In these cases, MCA territorial infarction was verified by follow-up computed tomographic scan 24 hours after symptom onset. We excluded patients with lacunar infarctions as seen on brain imaging, bilateral lesions, coincidental intracranial hemorrhage, concomitant ischemia in the posterior circulation, or a history of stroke. After hospital admission, the neurological deficit was quantified using the National Institutes of Health Stroke Scale score. Baseline characteristics of the study population, as well as vascular risk factors, stroke etiology, and treatment, are shown in Table 1 . All patients or next of kin gave informed consent for study participation and for determination of the S100B values. The study was approved by the ethics review committee of our university hospital.
BLOOD SAMPLING AND S100B MEASUREMENTS
Venous blood samples (2 mL) were drawn at hospital admission (baseline) and 24, 48, 72, 96, 120, and 144 hours after symptom onset. Blood samples were centrifuged (at 2703g for 5 minutes), and serum was stored at −25°C. Two patients died during the study period of malignant MCA infarction, for whom final blood sampling occurred after 96 and 120 hours.
For measurement of the S100B serum concentrations, we used a commercially available monoclonal 2-site immunoluminometric assay and a fully automatic LIA-mat system (Byk-Sangtec Diagnostica, Dietzenbach, Germany), which measures the ␤ subunit of protein S100 as defined by 3 monoclonal antibodies (SMST 12, SMSK 25, and SMSK 28). The detection limit of this kit was 0.02 µg/L. Intra-assay and interassay variabilities were 2.8% to 6.4% and 2.2% to 10.7%, respectively.
LONG-TERM OUTCOME
Six months after stroke, functional outcome was assessed by a neurologist (O.C.S.) using the modified Rankin Scale (mRS). 1 Patients who died within the first 6 months were scored as mRS 6. By means of this scale, functional outcome was dichotomized as independent (mRS score, 0-2) or as dependent or dead (mRS score, 3-5 or 6).
1
INFARCT VOLUMETRY
Infarct volume was based on fluid-attenuated inversion recovery magnetic resonance imaging (n=25) or computed tomographic scanning (n=12) performed on day 7 after symptom onset. For infarct magnetic resonance imaging volumetry, we used commercially available software (MRVision; MRVision Inc, Winchester, Mass), and for computed tomographic scans we used public domain software (National Institutes of Health, Bethesda, Md). For the 2 patients who died between days 4 and 6, follow-up imaging was not obtained. Measurements of lesion volume were performed independently by 2 observers (O.C.S. and R.M.R.); one of them was blinded to all other data. The mean ± SD infarct volume measured by the blinded observer was 133.2 ± 157.0 mL, and that by the unblinded observer was 142.6 ± 171.0 mL. Interobserver agreement revealed a single-measure intraclass correlation coefficient of 0.98 (95% confidence interval, 0.96-0.99; Cronbach ␣=.99). Final analysis was based on the consensus achieved between both observers at joint reevaluation of their data previously obtained independently.
STATISTICAL ANALYSIS
All statistical analyses were performed using the SPSS 10.0 software package (SPSS Inc, Chicago, Ill). The S100B AUC and peak value (defined as the highest individual value followed by a subsequent decrease) were derived from each S100B kinetic. To assess the predictive value of S100B with respect to functional outcome, we first calculated bivariate correlations (Spearman ) between the S100B measures and the actual mRS values. Second, using receiver operating characteristic curve analysis, cut points for the corresponding S100B values were determined, and accuracy measures for predicting a dichotomized functional state 6 months after stroke (ie, independent vs dependent or dead) were derived from cross-tabulations. A 2 statistic was used to indicate significant findings. Third, multivariate stepwise logistic regression analysis was performed to estimate whether S100B (ie, 48-hour value and AUC) is independently predictive of functional outcome. To check multicollinearity between the independent variables, we performed bivariate Spearman correlations. Despite significant correlation (PϽ.001) between the initial National Institutes of Health Stroke Scale scores and the corresponding S100B values (=0.58 and =0.60, respectively), no significant multicollinearity was found.
To quantify the relationship between S100B level and infarct volume, we calculated bivariate Spearman correlations. Furthermore, to estimate final infarct volume from S100B values, we performed univariate linear regression analysis after log transformation for normalizing the S100B and infarct volume distribution. Because several consecutive statistical tests were performed, ␣ adjustment according to the modified Bonferroni procedure was applied at each step of analysis.
RESULTS
S100B KINETIC
The S100B serum concentrations at hospital admission (baseline) ranged from 0.04 to 0.36 µg/L (mean ± SD, 0.12±0.07 µg/L). In 33 (85%) of 39 patients, an S100B peak value according to our definition (ie, with subsequent decrease) could be detected, with peak concentrations ranging from 0.08 to 12.20 µg/L (mean ± SD, 2.49 ± 3.41 µg/L). Peak values occurred 24 hours after stroke in 8 patients, 48 hours after stroke in 10 patients, 72 hours after stroke in 9 patients, 96 hours after stroke in 3 patients, and 120 hours after stroke in 3 patients. The S100B AUC ranged from 7.0 to 931.9 µg/L · h (mean±SD, 196.5 ± 267.5 µg/L · h).
LONG-TERM OUTCOME
Functional outcome 6 months after stroke was obtained in 38 patients; 1 patient was not available for follow-up. Nine patients had already died (mRS score, 6). Fourteen patients were moderately or severely disabled (mRS score, [3] [4] [5] , and the remaining 15 patients were slightly disabled or showed no symptoms (mRS score, 0-2). Table 2 provides results of the bivariate correlation (Spearman ) between various S100B measures and the mRS scores, revealing highly significant coefficients ranging from 0.53 to 0.68. This indicates that higher S100B values were associated with higher mRS scores. Single S100B values obtained 48 and 72 hours after stroke onset were correlated with the corresponding mRS scores as high as the AUC and the peak value. Derived using receiver operating characteristic curve analysis, we calculated cut points that provided optimal sensitivities and specificities. Based on these cut points, Table 2 provides accuracy measures predicting functional state 6 months after stroke. The 48-and 72-hour S100B values provided an 82% overall accuracy, and the AUC and peak value also did not provide superior accuracy. In a multivariate stepwise logistic regression model that included age, sex, lesion side, National Institutes of Health Stroke Scale score, vascular risk factors, and stroke etiology, S100B emerged as an independent outcome predictor ( Table 3) .
INFARCT VOLUME
Final infarct volume varied between 2.8 and 555.5 mL (mean±SD, 150.5±172.3 mL). Using univariate linear regression analysis (Table 4) , all S100B values were significantly associated with final infarct volume, whereas single S100B values obtained 48 and 72 hours after stroke onset, as well as the AUC and peak value, provided the highest correlation coefficients. Scatterplots and the corresponding regression curves are displayed in the Figure for the 48-hour S100B value, AUC, and peak value. Abbreviation: Exp(␤), exponential ␤. *Due to collinearity between the National Institutes of Health Stroke Scale (NIHSS) scores and the S100B values, both models were recalculated after the exclusion of the NIHSS scores, which did not alter the significance of the models. 
COMMENT
In the present study, single measures of the S100B serum concentration obtained 48 and 72 hours after stroke onset were highly correlated with long-term outcome and infarct volume. For each of these single S100B values, the diagnostic accuracy of predicting an independent state of the patient was as high as for the more complex measures of the S100B kinetic (ie, the AUC or peak value) and reached an overall accuracy of 82%. Furthermore, based on a single S100B value, infarct volume could be calculated using a linear model. Therefore, we conclude that single S100B values obtained 48 and 72 hours after stroke onset may be ideal to use as easily accessible and valid surrogate markers for future interventional trials of nonlacunar MCA infarctions.
There are good arguments favoring S100B as a measure ofeffectivenessindifferenttypesofacuteinterventionalstroke trials. For thrombolytic studies, it has been shown that lesion volume may constitute a meaningful surrogate marker of successful treatment. A post hoc analysis of the imaging data of the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial 4 showed significantly smaller lesion volumes in the recombinant tissue plasminogen activator-treated group. Furthermore, it has been shown that S100B level, in particular a 48-hour S100B value of less than 0.4 µg/L, is an indicator of MCA recanalization within 6 hours of stroke onset, based on a high sensitivity and specificity (overall accuracy, 95%).
14 Therefore, early and sufficient recanalization of an occluded intracranial artery is associatedwithsmallerinfarctsandbetteroutcome.Thereby, the effectiveness of a recanalizing intervention can be closely gauged by serum S100B level, and a single value appears to be as predictive as more complex measures of the S100B kinetic. 14 The failure of previous investigations of various neuroprotective agents was not necessarily because of the ineffectiveness of the agents under study but, rather, because of shortcomings with respect to study design and patient selection criteria. 15 For example, the optimal time point and duration for the application in humans of one neuroprotective drug that was evaluated are unknown. 15 It is likely but not proved that patients with potentially salvageable but hypoperfused brain tissue ("ischemic penumbra") may obtain benefits from neuroprotective treatment. 15 In this context, S100B level may function as a useful marker of tissue damage, helping to identify optimal conditions for the application of a neuroprotective drug. In a recent study 16 investigating the effect of recombinant human erythropoietin (rhEPO) in acute MCA infarction within 8 hours after stroke onset, S100B level was used as a secondary end point. The authors reported a significantly better outcome 30 days after stroke as measured by the Barthel Index and a trend toward an improved outcome as measured by the mRS score in the rhEPO-treated group. 16 Supporting our hypothesis, the S100B serum values were significantly lower in the rhEPO-treated group compared with the placebo-treated group (mean S100B level, 0.76 vs 0.43 µg/L on day 7 after stroke). 16 Unfortunately,inthissmalltrial(21rhEPO-treated and 19 placebo-treated patients), the S100B values obtained 3 days after stroke onset did not differentiate between the 2 treatment groups, suggesting no positive effect of rhEPO at that time point. 16 This is not in conflict with our results, because we compared patient groups with an independent vs a dependent or dead status 6 months after stroke (Table 2) . In their rhEPO-treated group, Ehrenreich et al 16 reported only 3 additional patients who were independent 30 days after stroke according to the mRS score, which is not significant. Furthermore, more than 10% of all patients in their trial experienced a lacunar stroke, in which S100B levels do not increase significantly. 12 On the other hand, it is conceivable that neuroprotective strategies may have positive effects on the S100B kinetic at a later stage compared with recanalizing interventions because of inhibition of secondary tissue damage. 17 Nevertheless, results of the rhEPO trial 16 suggest that S100B may be a useful surrogate marker in neuroprotective proof-of-principle studies. The present study harbors some shortcomings. Because of the small sample size, the defined S100B cut points and the corresponding accuracy measures may be uncertain and should be reconfirmed in a larger sample. Furthermore, as suggested in the Figure, there may be a potentially nonlinear relationship between the various S100B measures and the final infarct volume. All statistical analyses used in the present study assume linearity between the variables. This may have some unknown effect on the results obtained. Finally, the range of intraassay and interassay variability for the S100B determination was large and may affect reproducibility of single measurements. In conclusion, the prediction of longterm outcome and final infarct volume by single S100B measurements, as demonstrated in the present study, may help to establish S100B as an easily accessible, inexpensive, and valid surrogate marker in future stroke trials. 
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